CA2301852C - Angiogenesis promoters and angiogenesis potentiators - Google Patents
Angiogenesis promoters and angiogenesis potentiators Download PDFInfo
- Publication number
- CA2301852C CA2301852C CA002301852A CA2301852A CA2301852C CA 2301852 C CA2301852 C CA 2301852C CA 002301852 A CA002301852 A CA 002301852A CA 2301852 A CA2301852 A CA 2301852A CA 2301852 C CA2301852 C CA 2301852C
- Authority
- CA
- Canada
- Prior art keywords
- hydrogen atom
- pharmaceutical composition
- group
- halogen atom
- pyridazinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 32
- -1 pyridazinone compound Chemical class 0.000 claims abstract description 52
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 25
- 230000002491 angiogenic effect Effects 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 230000003389 potentiating effect Effects 0.000 claims abstract description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 36
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 20
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 20
- 230000001737 promoting effect Effects 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- YJMYSLFFZJUXOA-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 YJMYSLFFZJUXOA-UHFFFAOYSA-N 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 238000002266 amputation Methods 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 229940126062 Compound A Drugs 0.000 description 27
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 27
- 239000003981 vehicle Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 102000001554 Hemoglobins Human genes 0.000 description 16
- 108010054147 Hemoglobins Proteins 0.000 description 16
- 241000700159 Rattus Species 0.000 description 12
- 229920000609 methyl cellulose Polymers 0.000 description 10
- 239000001923 methylcellulose Substances 0.000 description 10
- 235000010981 methylcellulose Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 2
- QWGUGDYWUADMGB-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 QWGUGDYWUADMGB-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000009963 pathologic angiogenesis Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- WRTJKSNOFQWXAW-UHFFFAOYSA-N 5-bromo-3-(2,2-dimethyl-3-phenylpropoxy)-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=CC=CC=1CC(C)(C)COC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 WRTJKSNOFQWXAW-UHFFFAOYSA-N 0.000 description 1
- LUZTWTFDRPMZPE-UHFFFAOYSA-N 5-bromo-3-(3-phenylpropoxy)-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=CC=CC=1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 LUZTWTFDRPMZPE-UHFFFAOYSA-N 0.000 description 1
- CSHCYQVKCLCXTK-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1CC(C)(C)COC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 CSHCYQVKCLCXTK-UHFFFAOYSA-N 0.000 description 1
- OHXOFHSIHYVYMH-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)-2-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1CC(O)COC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 OHXOFHSIHYVYMH-UHFFFAOYSA-N 0.000 description 1
- HZVJNIUTIWSMAC-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)-3-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1C(O)CCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 HZVJNIUTIWSMAC-UHFFFAOYSA-N 0.000 description 1
- PMLVYXZNSHKMEP-UHFFFAOYSA-N 5-chloro-3-(2,2-dimethyl-3-phenylpropoxy)-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=CC=CC=1CC(C)(C)COC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 PMLVYXZNSHKMEP-UHFFFAOYSA-N 0.000 description 1
- AVGCJKOSOVAHOX-UHFFFAOYSA-N 5-chloro-3-(3-phenylpropoxy)-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=CC=CC=1CCCOC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 AVGCJKOSOVAHOX-UHFFFAOYSA-N 0.000 description 1
- QKKAMFKZZRZEID-UHFFFAOYSA-N 5-chloro-3-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1CC(C)(C)COC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 QKKAMFKZZRZEID-UHFFFAOYSA-N 0.000 description 1
- ADAGMNCCEJMUMC-UHFFFAOYSA-N 5-chloro-3-[3-(4-chlorophenyl)-2-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1CC(O)COC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 ADAGMNCCEJMUMC-UHFFFAOYSA-N 0.000 description 1
- PUFKGXCMRBRRMQ-UHFFFAOYSA-N 5-chloro-3-[3-(4-chlorophenyl)-3-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1C(O)CCOC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 PUFKGXCMRBRRMQ-UHFFFAOYSA-N 0.000 description 1
- QQPNYUDCLZIZNS-UHFFFAOYSA-N 5-chloro-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 QQPNYUDCLZIZNS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000733322 Platea Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
An angiogenesis promoter and angiogenesis potentiator containing a pyridazinone compound of the formula (I) (see formula I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof, as an active ingredient.
The pyridazinone compound (I) and a pharmacologically acceptable salt thereof in the present invention promote angiogenesis and potentiate the angiogenic effect of a drug having such effect, and are useful as an angiogenesis promoter and angiogenesis potentiator.
The pyridazinone compound (I) and a pharmacologically acceptable salt thereof in the present invention promote angiogenesis and potentiate the angiogenic effect of a drug having such effect, and are useful as an angiogenesis promoter and angiogenesis potentiator.
Description
SPECIFICATION
ANGIOGENESIS PROMOTERS AND ANGIOGENESIS POTENTIATORS
Technical Field The present invention relates to angiogenesis promoters and angiogenesis potentiators, which contain, as an active ingredient, a specific pyridazinone compound or a pharmacologically acceptable salt thereof.
Background Art The below-noted specific pyridazinone compound in the present invention is known to have superior platelet aggregation inhibitory effect, cardiotonic effect, vasodilating effect, anti-SRS-A (Slow Reacting Substances of Anaphylaxis) effect, thromboxane A2 synthase inhibitory effect and the like (JP-B-7-107055, JP-A-7-285869), and is a drug expected to be an antiplatelet agent and the like.
However, there has not been any report on the effect of the pyridazinone compound on angiogenesis.
Disclosure of the Invention The present inventors have conducted various studies of the effect of the pyridazinone compound on the angiogenesis and found that the pyridazinone compound promotes angiogenesis and potentiates an angiogenic effect of a drug having such effect, which resulted in the completion of the present invention.
Accordingly, the present invention provides the following.
An angiogenesis promoter containing a pyridazinone compound of the formula (I) R,, X
N
i R2 N (I) HC-A
Y
wherein Rl, R 2 and R3 are each independently a hydrogen atom or a lower alkyl, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is C1 - CB alkylene optionally substituted by hydroxyl group, or a pharmacologically acceptable salt thereof (hereinafter to be referred to as pyridazinone compounds) as an active ingredient.
A method of promoting angiogenesis, which comprises administering a pyridazinone compound.
Use of a pyridazinone compound for the production of an angiogenesis promoter.
A pharmaceutical composition for promoting angiogenesis, which comprises a pyridazinone compound and a pharmaceutically acceptable carrier.
A commercial package comprising the above-mentioned pharmaceutical composition, and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for promoting angiogenesis.
A potentiator of a drug having an angiogenic effect, which contains a pyridazinone compound as an active ingredient.
A method of potentiating an angiogenic effect of a drug having such effect, which comprises administering a pyridazinone compound.
Use of a pyridazinone compound for the production of a potentiator of a drug having an angiogenic effect.
A pharmaceutical composition for potentiating an angiogenic effect of a drug having such effect, which contains a pyridazinone compound and a pharmaceutically acceptable carrier.
A commercial package comprising the above-mentioned pharmaceutical composition, and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for potentiating an angiogenic effect of a drug having such effect.
The pyridazinone compound in the present invention is preferably a compound of the formula (I), wherein R' and R 2 are each hydrogen atom, R3 is hydrogen atom or alkyl having 1 to 4 carbon atoms, X is halogen atom, Y is halogen atom or hydrogen atom and A is C1 -C5 alkylene optionally substituted by hydroxyl group.
Particularly preferable pyridazinone compound of the formula (I) (hereinafter to be referred to as pyridazinone compound (I)) is, for example, 4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3-(2H)-pyridazinone.
Angiogenesis means that endothelial cells bud from an existing blood vessel and form a new blood vessel. The process of the formation is complicated and is an important phenomenon observed in various aspects in the living body, such as angiogenesis for development and growth, pathologic angiogenesis (e.g. growth of tumor, diabetic retinopathy) and the like.
Administration of an angiogenesis promoter to the patients with cancer or diabetic retinopathy is prohibited because it promotes pathologic angiogenesis.
However, an angiogenesis promoter is useful in that it complements and potentiates the efficacy of a pharmaceutical agent that directly acts on the mainly diseased artery (artery mainly causing the disease), because it forms a collateral circulatory path irrespective of the mainly diseased artery.
The symbols used in this specification are explained in the following.
The lower alkyl at Rl, R2 and R3 has 1 to 6 carbon atoms and may be linear or branched. Examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, hexyl and the like.
Rl and R2 are each preferably a hydrogen atom and R3 is preferably a hydrogen atom or alkyl having 1 to 4 carbon atoms.
The alkyl having 1 to 4 carbon atoms at R3 is exemplified by methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl and the like.
The halogen atom at X and Y means fluorine atom, chlorine atom, bromine atom or iodine atom.
Preferable X is a halogen atom and preferable Y is a halogen atom and a hydrogen atom.
The C1 - C. alkylene optionally substituted by hydroxyl group at Amay be linear or branched and is exemplified by methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, 2,2-dimethylethylene, 2, 2 -diethyl ethylene, 2,2-di-n-propylethylene, hydroxymethylene, 1-hydroxyethylene, 2-hydroxyethylene, 3-hydroxypropylene and the like.
Preferable A is C1 - C5 alkylene optionally substituted by hydroxyl group.
In the formula (I), methylene group and pyridine ring may be bonded at any position, but preferably bonded at the 3-position relative to the nitrogen atom of the pyridine ring.
Y may be substituted at any position on the benzene ring, but preferably at the 4-position.
Particularly, the pyridazinone compound of the formula (I) wherein R' and RZ are hydrogen atoms, R3 is hydrogen atom or alkyl having 1 to 4 carbon atoms, X is halogen atom, Y is halogen atom or hydrogen atom and A is C1 - C5 alkylene optionally substituted by hydroxyl group is preferable.
More preferable pyridazinone compounds (I) include 4-bromo-6-(3-phenylpropoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-(3-phenylpropoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-(2,2-dimethyl-3-phenylpropoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-(2,2-dimethyl-3-phenylpropoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-2-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone and 4-chloro-6-[3-(4-chlorophenyl)-2-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.
The pyridazinone compound (I) in the present invention encompasses stereoisomers and optical isomers.
The pyridazinone compound (I) can be produced by a method disclosed in, for example, JP-B-7-107055, US-A-5314883, EP-A-482208, JP-A-7-252237, US-A-5750523 and EP-A-742211.
The pharmacologically acceptable salts of pyridazinone compound (I) include salts with inorganic acid (e.g., hydrochloride, hydrobromide, phosphate, sulfate and the like), salts with organic acid (e.g., acetate, succinate, maleate, fumarate, malate, tartrate and the like), and the like.
The pyridazinone compound (I) can be converted to the above-mentioned salts by known methods.
The pyri.dazinone c.ompound ( I)<-ind ptlannacologically acceptable salts thereof can be used as an angiogenesis promoter by themselves.
They may be also used as a pot:ent.iator of the ang:iogenic effect of a drug having such effect by concurrently using the drug.
The drug having an anq i..ogenic r:~f fect may be a qr_owth factor such as a basic fibroblast grooath factor;b-FGF, an endothelial cell growth factor;ECGF, an epidermal growth factor;EGF, a tr.ansforming growth factor-(t;TGF-Jr, a platea.et-derived endothelial cell growth factor;PDGF, a vascular endothelial growth factor;VEGF, a vascular perrneability factor;VPF zand the like, hepari.n, adenosine and the like.
The pyridazinone compound (I) and pharmacologically acceptable salts thereof are superior as a potent.i_at.or of the angiogenic effect of a growth factor, particularly b-FGF.
The effects of the preserit invention can be confirmed by any known method which is free of limitation.
The pyridazinone compound (I) and pharmacologically acceptable salts thereof, which are the active :ingredi.ents in the present invention, are extremely law toxic arid show an angioc:lenesis-promoting effect and potentiation of ttie angioqeni.c effect of a drug in mammals such as human, dog, cow, horse, rabbit, mouse, rat and the like.
The pyridazinone compound ( I) and pharmacologically acceptable salts thereof can be admirristered parenterally in the form of injection (subcutaneous, intravenous, intramuscular, intraperitoneal injections), ointment, suppository, aerosol agent and the like, or orally i_n the form of tablet, capsul e, granule, pill,, syrup, liquid, emulsion, suspension and the 1ike.
The pyridazinone compound (1) and salts thereof can be formulated into a preparation for administration, according to conventional methods of drug production.
The tablet, c:apsu.l..e, granule arid pil.l for oral administration can be prepared using excipient (e.g., sucrose, lactose, glucose, starch, mannitol and the .L.:ike ), binder ( e. g., syrup, acacia, gelatin, sorbitol, tragacanth, methylcellulose, polyvinylpyrrolidone and the like), disintegrant (e.g., starch, c:arboxymethylcellulose or calcium salt thereof, microcrystalline cellulose, polyethylene glycol and the like), lubricant (e.g., talc, magnesium stearate, calcium stearate, silica and the like), gli..dant (e.g., sodium lauryl. sulfate, glycerol and the like), and the like.
The injection, aerosol agent, syrup, liquid, emulsion and suspension can be prepared using a solvent for the active ingredient (e.g., water, ethyl alcohol, isopropyl alcohol, propylene glycol, 1,3-butylene glycol, polyethylene glycol and the like), a surfactant (e.g., sorbitan fatty acid ester, polyoxyethylenesorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene ether of hydrogenated caster oil, lecithin and the like), a suspending agent (e.g., cellulose derivatives such as carboxymethylcellulose sodium salt, methylcellulose and the like, natural gums such as tragacanth, acacia and the like), a preservative (e.g., p-hydroxybenzoate, benzalkonium chloride, sorbate and the like), and the like. A
suppository can be prepared using, for example, polyethylene glycol, lanolin, coconut oil and the like.
The dose of the pyridazinone compound (I) and a salt thereof can be determined as appropriate according to the age, body weight, disease state and the like of the patient. It is generally 0.001 mg - 5 g/day, preferably 0.005 - 1000 mg/day, for an adult ( human ), which is administered in one to several doses a day.
When the pyridazinone compound (I) or a pharmacologically acceptable salt thereof is used as a potentiator of the angiogenic effect of a drug having such effect, the pyridazinone compound in the present invention and the drug having an angiogenic effect are administered in such a manner that they are both present in the body during the same period of time. The use and dose of the drug having an angiogenic effect are free of limitation as long as they fall within the known ranges. They may be prepared into a single pharmaceutical preparation or separately into individual preparations. When they are separate preparations, the administration route and dose may be the same or different.
Brief Description of the Drawings Fig. 1 is a photograph showing the neovascularized blood vessel at day 7 of the test in a rat sponge model group administered with a vehicle.
Fig. 2 is a photograph showing the neovascularized blood vessels at day 7 of the test in a rat sponge model group administered with compound A.
Fig. 3 shows the amount of hemoglobin in sponge in a rat sponge model, indicating the angiogenesis-promoting effect of compound A.
ANGIOGENESIS PROMOTERS AND ANGIOGENESIS POTENTIATORS
Technical Field The present invention relates to angiogenesis promoters and angiogenesis potentiators, which contain, as an active ingredient, a specific pyridazinone compound or a pharmacologically acceptable salt thereof.
Background Art The below-noted specific pyridazinone compound in the present invention is known to have superior platelet aggregation inhibitory effect, cardiotonic effect, vasodilating effect, anti-SRS-A (Slow Reacting Substances of Anaphylaxis) effect, thromboxane A2 synthase inhibitory effect and the like (JP-B-7-107055, JP-A-7-285869), and is a drug expected to be an antiplatelet agent and the like.
However, there has not been any report on the effect of the pyridazinone compound on angiogenesis.
Disclosure of the Invention The present inventors have conducted various studies of the effect of the pyridazinone compound on the angiogenesis and found that the pyridazinone compound promotes angiogenesis and potentiates an angiogenic effect of a drug having such effect, which resulted in the completion of the present invention.
Accordingly, the present invention provides the following.
An angiogenesis promoter containing a pyridazinone compound of the formula (I) R,, X
N
i R2 N (I) HC-A
Y
wherein Rl, R 2 and R3 are each independently a hydrogen atom or a lower alkyl, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is C1 - CB alkylene optionally substituted by hydroxyl group, or a pharmacologically acceptable salt thereof (hereinafter to be referred to as pyridazinone compounds) as an active ingredient.
A method of promoting angiogenesis, which comprises administering a pyridazinone compound.
Use of a pyridazinone compound for the production of an angiogenesis promoter.
A pharmaceutical composition for promoting angiogenesis, which comprises a pyridazinone compound and a pharmaceutically acceptable carrier.
A commercial package comprising the above-mentioned pharmaceutical composition, and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for promoting angiogenesis.
A potentiator of a drug having an angiogenic effect, which contains a pyridazinone compound as an active ingredient.
A method of potentiating an angiogenic effect of a drug having such effect, which comprises administering a pyridazinone compound.
Use of a pyridazinone compound for the production of a potentiator of a drug having an angiogenic effect.
A pharmaceutical composition for potentiating an angiogenic effect of a drug having such effect, which contains a pyridazinone compound and a pharmaceutically acceptable carrier.
A commercial package comprising the above-mentioned pharmaceutical composition, and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for potentiating an angiogenic effect of a drug having such effect.
The pyridazinone compound in the present invention is preferably a compound of the formula (I), wherein R' and R 2 are each hydrogen atom, R3 is hydrogen atom or alkyl having 1 to 4 carbon atoms, X is halogen atom, Y is halogen atom or hydrogen atom and A is C1 -C5 alkylene optionally substituted by hydroxyl group.
Particularly preferable pyridazinone compound of the formula (I) (hereinafter to be referred to as pyridazinone compound (I)) is, for example, 4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3-(2H)-pyridazinone.
Angiogenesis means that endothelial cells bud from an existing blood vessel and form a new blood vessel. The process of the formation is complicated and is an important phenomenon observed in various aspects in the living body, such as angiogenesis for development and growth, pathologic angiogenesis (e.g. growth of tumor, diabetic retinopathy) and the like.
Administration of an angiogenesis promoter to the patients with cancer or diabetic retinopathy is prohibited because it promotes pathologic angiogenesis.
However, an angiogenesis promoter is useful in that it complements and potentiates the efficacy of a pharmaceutical agent that directly acts on the mainly diseased artery (artery mainly causing the disease), because it forms a collateral circulatory path irrespective of the mainly diseased artery.
The symbols used in this specification are explained in the following.
The lower alkyl at Rl, R2 and R3 has 1 to 6 carbon atoms and may be linear or branched. Examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, hexyl and the like.
Rl and R2 are each preferably a hydrogen atom and R3 is preferably a hydrogen atom or alkyl having 1 to 4 carbon atoms.
The alkyl having 1 to 4 carbon atoms at R3 is exemplified by methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl and the like.
The halogen atom at X and Y means fluorine atom, chlorine atom, bromine atom or iodine atom.
Preferable X is a halogen atom and preferable Y is a halogen atom and a hydrogen atom.
The C1 - C. alkylene optionally substituted by hydroxyl group at Amay be linear or branched and is exemplified by methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, 2,2-dimethylethylene, 2, 2 -diethyl ethylene, 2,2-di-n-propylethylene, hydroxymethylene, 1-hydroxyethylene, 2-hydroxyethylene, 3-hydroxypropylene and the like.
Preferable A is C1 - C5 alkylene optionally substituted by hydroxyl group.
In the formula (I), methylene group and pyridine ring may be bonded at any position, but preferably bonded at the 3-position relative to the nitrogen atom of the pyridine ring.
Y may be substituted at any position on the benzene ring, but preferably at the 4-position.
Particularly, the pyridazinone compound of the formula (I) wherein R' and RZ are hydrogen atoms, R3 is hydrogen atom or alkyl having 1 to 4 carbon atoms, X is halogen atom, Y is halogen atom or hydrogen atom and A is C1 - C5 alkylene optionally substituted by hydroxyl group is preferable.
More preferable pyridazinone compounds (I) include 4-bromo-6-(3-phenylpropoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-(3-phenylpropoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-(2,2-dimethyl-3-phenylpropoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-(2,2-dimethyl-3-phenylpropoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-chloro-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-2-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone and 4-chloro-6-[3-(4-chlorophenyl)-2-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.
The pyridazinone compound (I) in the present invention encompasses stereoisomers and optical isomers.
The pyridazinone compound (I) can be produced by a method disclosed in, for example, JP-B-7-107055, US-A-5314883, EP-A-482208, JP-A-7-252237, US-A-5750523 and EP-A-742211.
The pharmacologically acceptable salts of pyridazinone compound (I) include salts with inorganic acid (e.g., hydrochloride, hydrobromide, phosphate, sulfate and the like), salts with organic acid (e.g., acetate, succinate, maleate, fumarate, malate, tartrate and the like), and the like.
The pyridazinone compound (I) can be converted to the above-mentioned salts by known methods.
The pyri.dazinone c.ompound ( I)<-ind ptlannacologically acceptable salts thereof can be used as an angiogenesis promoter by themselves.
They may be also used as a pot:ent.iator of the ang:iogenic effect of a drug having such effect by concurrently using the drug.
The drug having an anq i..ogenic r:~f fect may be a qr_owth factor such as a basic fibroblast grooath factor;b-FGF, an endothelial cell growth factor;ECGF, an epidermal growth factor;EGF, a tr.ansforming growth factor-(t;TGF-Jr, a platea.et-derived endothelial cell growth factor;PDGF, a vascular endothelial growth factor;VEGF, a vascular perrneability factor;VPF zand the like, hepari.n, adenosine and the like.
The pyridazinone compound (I) and pharmacologically acceptable salts thereof are superior as a potent.i_at.or of the angiogenic effect of a growth factor, particularly b-FGF.
The effects of the preserit invention can be confirmed by any known method which is free of limitation.
The pyridazinone compound (I) and pharmacologically acceptable salts thereof, which are the active :ingredi.ents in the present invention, are extremely law toxic arid show an angioc:lenesis-promoting effect and potentiation of ttie angioqeni.c effect of a drug in mammals such as human, dog, cow, horse, rabbit, mouse, rat and the like.
The pyridazinone compound ( I) and pharmacologically acceptable salts thereof can be admirristered parenterally in the form of injection (subcutaneous, intravenous, intramuscular, intraperitoneal injections), ointment, suppository, aerosol agent and the like, or orally i_n the form of tablet, capsul e, granule, pill,, syrup, liquid, emulsion, suspension and the 1ike.
The pyridazinone compound (1) and salts thereof can be formulated into a preparation for administration, according to conventional methods of drug production.
The tablet, c:apsu.l..e, granule arid pil.l for oral administration can be prepared using excipient (e.g., sucrose, lactose, glucose, starch, mannitol and the .L.:ike ), binder ( e. g., syrup, acacia, gelatin, sorbitol, tragacanth, methylcellulose, polyvinylpyrrolidone and the like), disintegrant (e.g., starch, c:arboxymethylcellulose or calcium salt thereof, microcrystalline cellulose, polyethylene glycol and the like), lubricant (e.g., talc, magnesium stearate, calcium stearate, silica and the like), gli..dant (e.g., sodium lauryl. sulfate, glycerol and the like), and the like.
The injection, aerosol agent, syrup, liquid, emulsion and suspension can be prepared using a solvent for the active ingredient (e.g., water, ethyl alcohol, isopropyl alcohol, propylene glycol, 1,3-butylene glycol, polyethylene glycol and the like), a surfactant (e.g., sorbitan fatty acid ester, polyoxyethylenesorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene ether of hydrogenated caster oil, lecithin and the like), a suspending agent (e.g., cellulose derivatives such as carboxymethylcellulose sodium salt, methylcellulose and the like, natural gums such as tragacanth, acacia and the like), a preservative (e.g., p-hydroxybenzoate, benzalkonium chloride, sorbate and the like), and the like. A
suppository can be prepared using, for example, polyethylene glycol, lanolin, coconut oil and the like.
The dose of the pyridazinone compound (I) and a salt thereof can be determined as appropriate according to the age, body weight, disease state and the like of the patient. It is generally 0.001 mg - 5 g/day, preferably 0.005 - 1000 mg/day, for an adult ( human ), which is administered in one to several doses a day.
When the pyridazinone compound (I) or a pharmacologically acceptable salt thereof is used as a potentiator of the angiogenic effect of a drug having such effect, the pyridazinone compound in the present invention and the drug having an angiogenic effect are administered in such a manner that they are both present in the body during the same period of time. The use and dose of the drug having an angiogenic effect are free of limitation as long as they fall within the known ranges. They may be prepared into a single pharmaceutical preparation or separately into individual preparations. When they are separate preparations, the administration route and dose may be the same or different.
Brief Description of the Drawings Fig. 1 is a photograph showing the neovascularized blood vessel at day 7 of the test in a rat sponge model group administered with a vehicle.
Fig. 2 is a photograph showing the neovascularized blood vessels at day 7 of the test in a rat sponge model group administered with compound A.
Fig. 3 shows the amount of hemoglobin in sponge in a rat sponge model, indicating the angiogenesis-promoting effect of compound A.
Fig. 4 is a photograph showing the neovascularized blood vessels at day 4 of the test in a rat sponge model group 1 administered with a BSA-physiological saline solution.
Fig. 5 is a photograph showing the neovascularized blood vessels at day 4 of the test in a rat sponge model group 2 administered solely with a basic fibroblast growth factor (b-FGF).
Fig. 6 is a photograph showing the neovascularized blood vessels at day 4 of the test in a rat sponge model group 3 co-administered with b-FGF and compound A.
Fig. 7 shows the amount of hemoglobin in sponge in a rat sponge model, indicating angiogenic potency of b-FGF by compound A.
Fig. 8 shows the relationship between the dose and angiogenic efficacy by compound A in a rat sponge model.
Examples The present invention is explained in detail in the following Examples and Experimental Examples. The invention is not limited by these Examples in any way.
Experimental Example 1: promotion of angiogenesis by compound A
Method:
Rats were anesthetized by intraperitoneal administration of sodium pentobarbital (50 mg/kg), and the dorsal median line was incised for about 1 cm and an air pocket was made subcutaneously at about 2.5 cm toward the tail side with a Kocher clamp. A hemostatic gelatin sponge ( Spongel , 10 mmXlO mmX7 mm; manufactured by Yamanouchi Pharmaceutical Co., Ltd.) impregnated with physiological saline was embedded therein. The opening was sutured and antisepticized to give a test animal model.
As a reagent, compound A(4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3-(2H)-pyridazinone hydrochloride, 100 mg) produced by a conventional method was suspended in 0.5% methylcellulose solution (100 ml) in a mortar and used.
As a control, a vehicle (0. 5% methylcellulose solution) was used.
The vehicle was obtained by dissolving methylcellulose (5 g, manufactured by Kishida Chemical Industries, Ltd.) in distilled water (1000 ml).
The reagent (compound A) and the vehicle were orally administered repeatedly from the day of sponge embedding at a dose of 10 ml/kg once a day for 4 days or 7 days. The administration was performed 30 minutes before anesthetizing the animal on the very day of embedding, and the sponge was removed on the next day of the final administration.
After 4 days or 7 days from the embedding, an excess amount of pentobarbital was intravenously injected to the animals for euthanasia.
The back was opened, and the tissue surrounding the embedded sponge was removed and the surface of the sponge was photographed. The sponge was taken out and placed in a 0. 1M aqueous ammonia (2 ml ), which was stood for 4 hr to extract hemoglobin in the sponge. The extract (100 Eil) was taken, and hemoglobin was quantitated using an assay kit (hemoglobin B-TESTWAKO; manufactured by Wako Pure Chemical Industries, Ltd.) and used as the index of angiogenesis. The amount of hemoglobin in the sponge was calculated by the following formula.
Amount of hemoglobin in sponge (mg/sponge) _ hemoglobin (mg) in extract (100 l) X 20 (total extract 2 ml) The obtained data were expressed in mean standard error. For the evaluation of the angiogenic effect, an unpaired t-test was performed using the animals administered with the drug for 4 days or 7 days and respective vehicle groups as control to examine significant difference. The significance was ascribed at less than 5% risk rate.
Results:
1. Observation of photograph Both the reagent (compound A) administration group and vehicle administration group showed an increase of neovascularized blood vessels on the sponge surface at day 4 and day 7 of the test in proportion to the number of days lapsed from the initiation of the test. At day 7 of the test, the reagent (compound A) administration group (Fig.
2) showed more neovascularized blood vessels than in the vehicle administration group (Fig. 1).
2. Amount of hemoglobin in sponge The results are shown in Table 1 and Fig. 3. Both the reagent (compound A) administration group and vehicle administration group showed an increase in the amount of hemoglobin in sponge at day 4 and day 7 of the test, in proportion to the number of days lapsed from the initiation of the test. At day 7 of the test, the reagent (compound A) administration group showed a significant increase as compared to the vehicle administration group.
Fig. 5 is a photograph showing the neovascularized blood vessels at day 4 of the test in a rat sponge model group 2 administered solely with a basic fibroblast growth factor (b-FGF).
Fig. 6 is a photograph showing the neovascularized blood vessels at day 4 of the test in a rat sponge model group 3 co-administered with b-FGF and compound A.
Fig. 7 shows the amount of hemoglobin in sponge in a rat sponge model, indicating angiogenic potency of b-FGF by compound A.
Fig. 8 shows the relationship between the dose and angiogenic efficacy by compound A in a rat sponge model.
Examples The present invention is explained in detail in the following Examples and Experimental Examples. The invention is not limited by these Examples in any way.
Experimental Example 1: promotion of angiogenesis by compound A
Method:
Rats were anesthetized by intraperitoneal administration of sodium pentobarbital (50 mg/kg), and the dorsal median line was incised for about 1 cm and an air pocket was made subcutaneously at about 2.5 cm toward the tail side with a Kocher clamp. A hemostatic gelatin sponge ( Spongel , 10 mmXlO mmX7 mm; manufactured by Yamanouchi Pharmaceutical Co., Ltd.) impregnated with physiological saline was embedded therein. The opening was sutured and antisepticized to give a test animal model.
As a reagent, compound A(4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3-(2H)-pyridazinone hydrochloride, 100 mg) produced by a conventional method was suspended in 0.5% methylcellulose solution (100 ml) in a mortar and used.
As a control, a vehicle (0. 5% methylcellulose solution) was used.
The vehicle was obtained by dissolving methylcellulose (5 g, manufactured by Kishida Chemical Industries, Ltd.) in distilled water (1000 ml).
The reagent (compound A) and the vehicle were orally administered repeatedly from the day of sponge embedding at a dose of 10 ml/kg once a day for 4 days or 7 days. The administration was performed 30 minutes before anesthetizing the animal on the very day of embedding, and the sponge was removed on the next day of the final administration.
After 4 days or 7 days from the embedding, an excess amount of pentobarbital was intravenously injected to the animals for euthanasia.
The back was opened, and the tissue surrounding the embedded sponge was removed and the surface of the sponge was photographed. The sponge was taken out and placed in a 0. 1M aqueous ammonia (2 ml ), which was stood for 4 hr to extract hemoglobin in the sponge. The extract (100 Eil) was taken, and hemoglobin was quantitated using an assay kit (hemoglobin B-TESTWAKO; manufactured by Wako Pure Chemical Industries, Ltd.) and used as the index of angiogenesis. The amount of hemoglobin in the sponge was calculated by the following formula.
Amount of hemoglobin in sponge (mg/sponge) _ hemoglobin (mg) in extract (100 l) X 20 (total extract 2 ml) The obtained data were expressed in mean standard error. For the evaluation of the angiogenic effect, an unpaired t-test was performed using the animals administered with the drug for 4 days or 7 days and respective vehicle groups as control to examine significant difference. The significance was ascribed at less than 5% risk rate.
Results:
1. Observation of photograph Both the reagent (compound A) administration group and vehicle administration group showed an increase of neovascularized blood vessels on the sponge surface at day 4 and day 7 of the test in proportion to the number of days lapsed from the initiation of the test. At day 7 of the test, the reagent (compound A) administration group (Fig.
2) showed more neovascularized blood vessels than in the vehicle administration group (Fig. 1).
2. Amount of hemoglobin in sponge The results are shown in Table 1 and Fig. 3. Both the reagent (compound A) administration group and vehicle administration group showed an increase in the amount of hemoglobin in sponge at day 4 and day 7 of the test, in proportion to the number of days lapsed from the initiation of the test. At day 7 of the test, the reagent (compound A) administration group showed a significant increase as compared to the vehicle administration group.
Table 1 Drug Hemoglobin in sponge (mg/sponge) 4 days after embedding 7 days after embedding Vehicle 6.216 0.903 ( 9) 9.585 0.774 (10) Reagent (compound A) 6.255 0.807 (10) 16.351 1.836 ** (9) ( ): number of animals **:p<0.01 relative to vehicle administration group, unpaired t-test Experimental Example 2 : potentiation of angiogenic effect of b-FGF
by compound A
Method:
The test animal models were prepared in the same manner as in Experimental Example 1.
As a reagent, compound A(4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3-(2H)-pyridazinone hydrochloride, 50 mg) produced by a conventional method was suspended in 0.5% methylcellulose solution (100 ml) in a mortar and used.
The vehicle (0.5% methylcellulose solution) was obtained by dissolving methylcellulose (5 g, manufactured by Kishida Chemical Industries, Ltd.) in distilled water (1000 ml).
A 0.1% bovine serum albumin (BSA) -physiological saline solution was prepared by dissolving BSA (0.1 g, Sigma) in physiological saline (100 ml).
A b-FGF solution was prepared by dissolving recombinant b-FGF
(20 g,manufactured by BTI) in 0.1% BSA-physiological saline solution (2 ml).
A hemostatic gelatin sponge was the same as that used in Experimental Example 1.
The test group was divided into 3 groups. A sponge wetted with 100 Eil of 0.1% BSA-physiological saline solution was embedded in group 1. A sponge (1 Eig b-FGF/sponge) wetted with b-FGF solution (100 111) was embedded in group 2 and group 3.
The vehicle was orally administered to group 1 and group 2, and the reagent (compound A) was orally administered to group 3 repeatedly frorn the day of sponge ernbedding at the dose of 10 nil/kq twice a day for 4 clays.
In every test group, the adnii_nist.rat_i.on began f.rom the evening (single administratiori) c:if: the very day of enibeddirig. The time of administration of the drt.7g was around 9 a.m. for the fi-r.st administratiori and around. 7 p.m. for the second administ:ration. In consideration of the effect of the druq, the drug was not adniinistered on the veL-y day of sponge .removal (7 times of admiriistration in total ).
After 4 days frorn the embedding, an excess amount of pentobarbital was intravenous]_y injected to the animals for euthanasia.
The back was opened, and the tissue surrounding the embedded sponge was removed and the surfacE:-> o f_ the sponge was photographed. The sponge was takerr out and hemoglobin =in the sporiqe was calculated in the same manner as in Exper:i.mental Example l.
The obtalned data were expressed in niean= _:standard error. For the evaluation of the angiogeni.c effect, a multiple comparison test by Tukey rnethod was performed to examino s:iqnif icant di_f_ference.. The signifacance was ascribed at. less than S , risk rate.
Result-1. Observation of photog.raph The results are shown in Fi.q. 4, Fi_q . 5 and Fiq . 6. At day 4 of the test, group 2 (b-FGF single admi_ni_stration group) visually showed more neovasculari.zed blood vesse:l.s than i.n group 1(0.10 BSA-physi_ological. sal.inc--! solution qroup), and group 3 (b-FGF and reagent ( compound A, 5 mg /kg ) co-admirii-stration group) showed still more neovascularized blc:,,od vessels ttiari i_n qr_oup 2.
2. Amount of hemog].obin in sponge The results are shown in Table 2 and Fig. 7. The group 3 (b-FGF
and reagent (compound A, 'i mg/ kg ) co-administration group ) showed a significant increase iri hemoglobin content as compared t:o group 1 (0. 1%
BSA-physioloyical sali_ne solution qroup) and group 2 (b-FGF single admini..stration group).
- r, Ta~)le 2 Test Hemoglobin in group Drug sponge (mg/sponge) at 4 Oral. administration In-sponge days after _ administration embeddin Group 1 Vehicle BSA-I.hysi_ologic:al 5. 503+0. 562 (10) s a.l ine Group 2 Vehicle b-FGF 7.285 0.715 (10) 14.995 2.307 Group 3 Reagent (compound A) b-FGF ++ ** 10 ( ) : number of an:imals, ++:p<0.01 relative to group 1., **: p<0 . 01. relati.ve to group ~' (Tukey niethod ) Experimental Example 3 : relationship between dose and angiogenesis proinotion by compound A
MethQdi The test. anirnal models were prepared in the same manner as in Experimental Example 1.
As a reagent, coml:~ound A(4-brorno-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyri(-iylmethylamino)-:3-(2H)--pyridazinone hydrochloride, 35 mg) produced by a convent.ional method was suspended in 0. 5% methylcellulose solution ("7 0 ml) in a mortar and used as a 5 mg/kg administration reagent.
This suspension was diluted two-fold and 5-fold with a vehicle (0.5% methylcellulose solution) to give 2.5 mg/kg administration reagent and 1mg/kg administration reagent (respective dose 10 m1./kg).
The vehicle (0.5% methyl.cellulose :_,olut:ion) was used as a control.
The vehicle was obtained by dissolving inethylcell.ulose (5 g, manufactured by Kishida C.hemical.Industries, Ltd.).in distilled water (1000 ml).
Each reagent (compound A) and the vehicle were orally administered repeatedly (7 tirnes in total) fr_om the day of sponge embedding at a dose of 10 ml/kg twice a day for 4 days. The sponge was removed on the next day of the final administration, and hemoglobin in the sponge was calcu::Lat.ed in the same manner as in Experimental Example 1.
Each group contained 8-9 animals and the obtained data were expressed iri mean standard error. For the evaluation of the :i 1 angiogenic effect, a Dunnett test was performed using the vehicle administration group as a control to examine significant difference.
The significance was ascribed at less than 5% risk rate.
Results-The results are shown in Fig. 8. As compared to the vehicle administration group, 2.5 mg/kg administration group and 5 mg/kg administration group showed a significant increase in hemoglobin amount.
In the 5 mg/kg administration group, the effect tended to weaken somewhat, though a significant difference was found. This is postulated to be attributable to a decrease in blood flow due to hypotensive action, since the dose (5 mg/kg) of compound A causes hypotensive action in rat, based on vasodilating action.
This has clarified that compound A shows superior angiogenesis promotion effect at a dose substantially free from hypotensive action.
Experimental Example 4 : toxicity The acute toxicity (LD50) of compound A was not less than 2 g/kg by the oral administration to rat and dog, and the compound was found to be extremely low toxic.
From the above test results, it is evident that the pyridazinone compound (I) and a salt thereof show superior angiogenesis-promoting effect and potentiation of the angiogenic effect of a drug having such effect, and are low toxic.
Example 1 (tablet) The following ingredients were mixed by a conventional method and prepared into sugar-coated tablets containing 50 mg of the active ingredient per tablet.
Compound A 10 g lactose 20 g starch 5 g magnesium stearate 0.1 g calcium carboxymethylcellulose 7 g total 42.1 g Example 2 (capsule) The following ingredients were mixed by a conventional method and filled in gelatin capsules to give capsules containing 50 mg of the active ingredient per capsule.
Coiilpound A 10 g lactose 20 g inicrocrystall_irie cellulose 10 g magnesiuni stearate 1 g total 41 g Example 3 (ointment) 'i'he following ingredients were niixed by a conventional inethod to give a 1 wt o ointmerit.
Compound A I g olive oil 20 g white petrolatum 79 g total 100 g Example 4 (aerosol suspension) Ttie following ingredients (A) were mixed arid the obtairied inixed so.lutiori was charged iri a container equipped with a valve. A
propellant (B) was pressed therein from a valve nozzle at 20"C to about 2.46 - 2.81 mg/cmz gauge pressure to give an aerosol suspension.
(A)Compound A 0.25 wt%
isopropyl iiiyristate 0.10 wt%
ethanol 26.40 wt%
(B)1,2-dichlorotetrafluoroethane and 1-chloropentafluoroethane (60-40 wt%) 73.25 wt%
Industrial Applicability The pyridazinone compound (I) and pharrnacologically acceptable salt thereof in the present invention promote angiogenesis and potentiate the angiogenic effect of a drug having such effect, and :30 are useful as ari angiogeriesis prolnoter and potentiator. 'I'tierefore, they are effective for the promotion of healing of various diseases wherein angiogenesi_s plays an iniportant role, suclr as promotion of wound healing, proinotiori of adhesiori after skin implantation, promotiori of healing after re-suture on quadruple amputation, trichogenous promotion and the like.
by compound A
Method:
The test animal models were prepared in the same manner as in Experimental Example 1.
As a reagent, compound A(4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3-(2H)-pyridazinone hydrochloride, 50 mg) produced by a conventional method was suspended in 0.5% methylcellulose solution (100 ml) in a mortar and used.
The vehicle (0.5% methylcellulose solution) was obtained by dissolving methylcellulose (5 g, manufactured by Kishida Chemical Industries, Ltd.) in distilled water (1000 ml).
A 0.1% bovine serum albumin (BSA) -physiological saline solution was prepared by dissolving BSA (0.1 g, Sigma) in physiological saline (100 ml).
A b-FGF solution was prepared by dissolving recombinant b-FGF
(20 g,manufactured by BTI) in 0.1% BSA-physiological saline solution (2 ml).
A hemostatic gelatin sponge was the same as that used in Experimental Example 1.
The test group was divided into 3 groups. A sponge wetted with 100 Eil of 0.1% BSA-physiological saline solution was embedded in group 1. A sponge (1 Eig b-FGF/sponge) wetted with b-FGF solution (100 111) was embedded in group 2 and group 3.
The vehicle was orally administered to group 1 and group 2, and the reagent (compound A) was orally administered to group 3 repeatedly frorn the day of sponge ernbedding at the dose of 10 nil/kq twice a day for 4 clays.
In every test group, the adnii_nist.rat_i.on began f.rom the evening (single administratiori) c:if: the very day of enibeddirig. The time of administration of the drt.7g was around 9 a.m. for the fi-r.st administratiori and around. 7 p.m. for the second administ:ration. In consideration of the effect of the druq, the drug was not adniinistered on the veL-y day of sponge .removal (7 times of admiriistration in total ).
After 4 days frorn the embedding, an excess amount of pentobarbital was intravenous]_y injected to the animals for euthanasia.
The back was opened, and the tissue surrounding the embedded sponge was removed and the surfacE:-> o f_ the sponge was photographed. The sponge was takerr out and hemoglobin =in the sporiqe was calculated in the same manner as in Exper:i.mental Example l.
The obtalned data were expressed in niean= _:standard error. For the evaluation of the angiogeni.c effect, a multiple comparison test by Tukey rnethod was performed to examino s:iqnif icant di_f_ference.. The signifacance was ascribed at. less than S , risk rate.
Result-1. Observation of photog.raph The results are shown in Fi.q. 4, Fi_q . 5 and Fiq . 6. At day 4 of the test, group 2 (b-FGF single admi_ni_stration group) visually showed more neovasculari.zed blood vesse:l.s than i.n group 1(0.10 BSA-physi_ological. sal.inc--! solution qroup), and group 3 (b-FGF and reagent ( compound A, 5 mg /kg ) co-admirii-stration group) showed still more neovascularized blc:,,od vessels ttiari i_n qr_oup 2.
2. Amount of hemog].obin in sponge The results are shown in Table 2 and Fig. 7. The group 3 (b-FGF
and reagent (compound A, 'i mg/ kg ) co-administration group ) showed a significant increase iri hemoglobin content as compared t:o group 1 (0. 1%
BSA-physioloyical sali_ne solution qroup) and group 2 (b-FGF single admini..stration group).
- r, Ta~)le 2 Test Hemoglobin in group Drug sponge (mg/sponge) at 4 Oral. administration In-sponge days after _ administration embeddin Group 1 Vehicle BSA-I.hysi_ologic:al 5. 503+0. 562 (10) s a.l ine Group 2 Vehicle b-FGF 7.285 0.715 (10) 14.995 2.307 Group 3 Reagent (compound A) b-FGF ++ ** 10 ( ) : number of an:imals, ++:p<0.01 relative to group 1., **: p<0 . 01. relati.ve to group ~' (Tukey niethod ) Experimental Example 3 : relationship between dose and angiogenesis proinotion by compound A
MethQdi The test. anirnal models were prepared in the same manner as in Experimental Example 1.
As a reagent, coml:~ound A(4-brorno-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyri(-iylmethylamino)-:3-(2H)--pyridazinone hydrochloride, 35 mg) produced by a convent.ional method was suspended in 0. 5% methylcellulose solution ("7 0 ml) in a mortar and used as a 5 mg/kg administration reagent.
This suspension was diluted two-fold and 5-fold with a vehicle (0.5% methylcellulose solution) to give 2.5 mg/kg administration reagent and 1mg/kg administration reagent (respective dose 10 m1./kg).
The vehicle (0.5% methyl.cellulose :_,olut:ion) was used as a control.
The vehicle was obtained by dissolving inethylcell.ulose (5 g, manufactured by Kishida C.hemical.Industries, Ltd.).in distilled water (1000 ml).
Each reagent (compound A) and the vehicle were orally administered repeatedly (7 tirnes in total) fr_om the day of sponge embedding at a dose of 10 ml/kg twice a day for 4 days. The sponge was removed on the next day of the final administration, and hemoglobin in the sponge was calcu::Lat.ed in the same manner as in Experimental Example 1.
Each group contained 8-9 animals and the obtained data were expressed iri mean standard error. For the evaluation of the :i 1 angiogenic effect, a Dunnett test was performed using the vehicle administration group as a control to examine significant difference.
The significance was ascribed at less than 5% risk rate.
Results-The results are shown in Fig. 8. As compared to the vehicle administration group, 2.5 mg/kg administration group and 5 mg/kg administration group showed a significant increase in hemoglobin amount.
In the 5 mg/kg administration group, the effect tended to weaken somewhat, though a significant difference was found. This is postulated to be attributable to a decrease in blood flow due to hypotensive action, since the dose (5 mg/kg) of compound A causes hypotensive action in rat, based on vasodilating action.
This has clarified that compound A shows superior angiogenesis promotion effect at a dose substantially free from hypotensive action.
Experimental Example 4 : toxicity The acute toxicity (LD50) of compound A was not less than 2 g/kg by the oral administration to rat and dog, and the compound was found to be extremely low toxic.
From the above test results, it is evident that the pyridazinone compound (I) and a salt thereof show superior angiogenesis-promoting effect and potentiation of the angiogenic effect of a drug having such effect, and are low toxic.
Example 1 (tablet) The following ingredients were mixed by a conventional method and prepared into sugar-coated tablets containing 50 mg of the active ingredient per tablet.
Compound A 10 g lactose 20 g starch 5 g magnesium stearate 0.1 g calcium carboxymethylcellulose 7 g total 42.1 g Example 2 (capsule) The following ingredients were mixed by a conventional method and filled in gelatin capsules to give capsules containing 50 mg of the active ingredient per capsule.
Coiilpound A 10 g lactose 20 g inicrocrystall_irie cellulose 10 g magnesiuni stearate 1 g total 41 g Example 3 (ointment) 'i'he following ingredients were niixed by a conventional inethod to give a 1 wt o ointmerit.
Compound A I g olive oil 20 g white petrolatum 79 g total 100 g Example 4 (aerosol suspension) Ttie following ingredients (A) were mixed arid the obtairied inixed so.lutiori was charged iri a container equipped with a valve. A
propellant (B) was pressed therein from a valve nozzle at 20"C to about 2.46 - 2.81 mg/cmz gauge pressure to give an aerosol suspension.
(A)Compound A 0.25 wt%
isopropyl iiiyristate 0.10 wt%
ethanol 26.40 wt%
(B)1,2-dichlorotetrafluoroethane and 1-chloropentafluoroethane (60-40 wt%) 73.25 wt%
Industrial Applicability The pyridazinone compound (I) and pharrnacologically acceptable salt thereof in the present invention promote angiogenesis and potentiate the angiogenic effect of a drug having such effect, and :30 are useful as ari angiogeriesis prolnoter and potentiator. 'I'tierefore, they are effective for the promotion of healing of various diseases wherein angiogenesi_s plays an iniportant role, suclr as promotion of wound healing, proinotiori of adhesiori after skin implantation, promotiori of healing after re-suture on quadruple amputation, trichogenous promotion and the like.
Claims (25)
1. A pharmaceutical composition for promoting angiogenesis, which comprises:
a pyridazinone compound of the formula (I):
wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl group; X is a halogen atom, a cyano group or a hydrogen atom; Y is a halogen atom, a trifluoromethyl group or a hydrogen atom; and A is a C1-C$
alkylene group optionally substituted by a hydroxyl group, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
a pyridazinone compound of the formula (I):
wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl group; X is a halogen atom, a cyano group or a hydrogen atom; Y is a halogen atom, a trifluoromethyl group or a hydrogen atom; and A is a C1-C$
alkylene group optionally substituted by a hydroxyl group, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein R1 and R 2 are each a hydrogen atom; R3 is a hydrogen atom or C1-C4 alkyl group; X is a halogen atom; Y is a halogen atom or a hydrogen atom; and A is a C1-C5 alkylene group optionally substituted by a hydroxyl group.
3. The pharmaceutical composition of claim 1, wherein the pyridazinone compound of the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.
4. A pharmaceutical composition for potentiating an angiogenic effect of a drug having such effect, which comprises:
a pyridazinone compound of the formula (I):
wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl group; X is a halogen atom, a cyano group or a hydrogen atom; Y is a halogen atom, a trifluoromethyl group or a hydrogen atom; and A is a C1-C8 alkylene group optionally substituted by a hydroxyl group, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
a pyridazinone compound of the formula (I):
wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl group; X is a halogen atom, a cyano group or a hydrogen atom; Y is a halogen atom, a trifluoromethyl group or a hydrogen atom; and A is a C1-C8 alkylene group optionally substituted by a hydroxyl group, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4, wherein R1 and R2 are each a hydrogen atom; R3 is a hydrogen atom or a C1-C4 alkyl group; X is a halogen atom; Y is a halogen atom or a hydrogen atom; and A is a C1-C5 alkylene group optionally substituted by a hydroxyl group.
6. The pharmaceutical composition of claim 4, wherein the pyridazinone compound of the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.
7. The pharmaceutical composition of any one of claims 4 to 6, wherein the drug having the angiogenic effect is a growth factor.
8. The pharmaceutical composition of claim 7, wherein the growth factor is a basic fibroblast growth factor.
9. Use of a pyridazinone compound of the formula (I):
wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl group; X is a halogen atom, a cyano group or a hydrogen atom; Y is a halogen atom, a trifluoromethyl group or a hydrogen atom; and A is a C1-C8 alkylene group optionally substituted by a hydroxyl group, or a pharmaceutically acceptable salt thereof, for promoting angiogenesis.
wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl group; X is a halogen atom, a cyano group or a hydrogen atom; Y is a halogen atom, a trifluoromethyl group or a hydrogen atom; and A is a C1-C8 alkylene group optionally substituted by a hydroxyl group, or a pharmaceutically acceptable salt thereof, for promoting angiogenesis.
10. The use of claim 9, wherein R1 and R2 are each a hydrogen atom; R3 is a hydrogen atom or a C1-C4 alkyl group;
X is a halogen atom; Y is a halogen atom or a hydrogen atom;
and A is a C1-C5 alkylene group optionally substituted by a hydroxyl group.
X is a halogen atom; Y is a halogen atom or a hydrogen atom;
and A is a C1-C5 alkylene group optionally substituted by a hydroxyl group.
11. The use of claim 9, wherein the pyridazinone compound of the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.
12. Use of a pyridazinone compound of the formula (I):
wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl group; X is a halogen atom, a cyano group or a hydrogen atom; Y is a halogen atom, a trifluoromethyl group or a hydrogen atom; and A is a C1-C8 alkylene group optionally substituted by a hydroxyl group, or a pharmaceutically acceptable salt thereof, for potentiating an angiogenic effect of a drug having such effect.
wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl group; X is a halogen atom, a cyano group or a hydrogen atom; Y is a halogen atom, a trifluoromethyl group or a hydrogen atom; and A is a C1-C8 alkylene group optionally substituted by a hydroxyl group, or a pharmaceutically acceptable salt thereof, for potentiating an angiogenic effect of a drug having such effect.
13. The use of claim 12, wherein R1 and R2 are each a hydrogen atom; R3 is a hydrogen atom or a C1-C4 alkyl group;
X is a halogen atom; Y is a halogen atom or a hydrogen atom;
and A is a C1-C5 alkylene group optionally substituted by a hydroxyl group.
X is a halogen atom; Y is a halogen atom or a hydrogen atom;
and A is a C1-C5 alkylene group optionally substituted by a hydroxyl group.
14. The use of claim 12, wherein the pyridazinone compound of the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)-propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.
15. The use of any one of claims 12 to 14, wherein the drug having the angiogenic effect is a growth factor.
16. The use of claim 15, wherein the growth factor is a basic fibroblast growth factor.
17. A commercial package which comprises:
the pharmaceutical composition of any one of claims 1 to 3; and a written matter associated therewith, the written matter stating that the pharmaceutical composition is used for promoting angiogenesis.
the pharmaceutical composition of any one of claims 1 to 3; and a written matter associated therewith, the written matter stating that the pharmaceutical composition is used for promoting angiogenesis.
18. A commercial package which comprises:
the pharmaceutical composition of any one of claims 4 to 8; and a written matter associated therewith, the written matter stating that the pharmaceutical composition is used for potentiating an angiogenic effect of a drug having such effect.
the pharmaceutical composition of any one of claims 4 to 8; and a written matter associated therewith, the written matter stating that the pharmaceutical composition is used for potentiating an angiogenic effect of a drug having such effect.
19. The pharmaceutical composition of any one of claims 4 to 8, which further comprises the drug having the angiogenic effect.
20. The pharmaceutical composition of claim 19, wherein the drug is a growth factor.
21. The pharmaceutical composition of claim 20, wherein the growth factor is a basic fibroblast growth factor.
22. The pharmaceutical composition according to any one of claims 1 to 3, which is used for promoting wound healing, for promoting adhesion after skin implantation, for promoting healing after re-suture on quadruple amputation or for trichogenous promotion.
23. The pharmaceutical composition according to any one of claims 4 to 8, which is used for promoting wound healing, for promoting adhesion after skin implantation, for promoting healing after re-suture on quadruple amputation or for trichogenous promotion.
24. The use according to any one of claims 9 to 11, which is for promoting wound healing, for promoting adhesion after skin implantation, for promoting healing after re-suture on quadruple amputation or for trichogenous promotion.
25. The use according to any one of claims 12 to 16, which is for promoting wound healing, for promoting adhesion after skin implantation, for promoting healing after re-suture on quadruple amputation or for trichogenous promotion.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23264497 | 1997-08-28 | ||
JP9/232644 | 1997-08-28 | ||
PCT/JP1998/003820 WO1999011268A1 (en) | 1997-08-28 | 1998-08-26 | Neovascularization promoters and neovascularization potentiators |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2301852A1 CA2301852A1 (en) | 1999-03-11 |
CA2301852C true CA2301852C (en) | 2007-07-10 |
Family
ID=16942531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002301852A Expired - Fee Related CA2301852C (en) | 1997-08-28 | 1998-08-26 | Angiogenesis promoters and angiogenesis potentiators |
Country Status (13)
Country | Link |
---|---|
US (1) | US6284758B1 (en) |
EP (1) | EP1025847B1 (en) |
JP (1) | JP4352613B2 (en) |
KR (1) | KR100559192B1 (en) |
CN (1) | CN1142779C (en) |
AT (1) | ATE307584T1 (en) |
AU (1) | AU8886298A (en) |
CA (1) | CA2301852C (en) |
DE (1) | DE69832089T2 (en) |
DK (1) | DK1025847T3 (en) |
ES (1) | ES2247716T3 (en) |
TW (1) | TW490303B (en) |
WO (1) | WO1999011268A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100633869B1 (en) * | 1998-12-07 | 2006-10-16 | 닛산 가가쿠 고교 가부시키 가이샤 | Remedial agent for erectile dysfunction |
EP1698339A4 (en) * | 2003-12-26 | 2009-06-17 | Nissan Chemical Ind Ltd | Neutrophilia inhibitor |
WO2005074938A1 (en) * | 2004-02-09 | 2005-08-18 | Nissan Chemical Industries, Ltd. | Drug for inhibiting vascular intimal hyperplasia |
AU2006270221B2 (en) | 2005-07-15 | 2012-01-19 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
EP2019657B1 (en) | 2006-04-26 | 2015-05-27 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
EP2111184B1 (en) | 2007-01-08 | 2018-07-25 | Micell Technologies, Inc. | Stents having biodegradable layers |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
CN101622003B (en) * | 2007-02-28 | 2012-03-21 | 日本株式会社Ltt生物医药 | Therapeutic agent for ameliorating prognosis after lower limb amputation surgery |
CA2688314C (en) | 2007-05-25 | 2013-12-03 | Micell Technologies, Inc. | Polymer films for medical device coating |
US8685432B2 (en) * | 2008-03-25 | 2014-04-01 | University Of Utah Research Foundation | Controlled release tissue graft combination biomaterials |
MX350637B (en) | 2008-04-17 | 2017-09-11 | Micell Technologies Inc | Stents having bioabsorbable layers. |
WO2010009335A1 (en) | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
WO2010111232A2 (en) | 2009-03-23 | 2010-09-30 | Micell Technologies, Inc. | Drug delivery medical device |
CN102481195B (en) | 2009-04-01 | 2015-03-25 | 米歇尔技术公司 | Drug delivery medical device |
CA2759015C (en) | 2009-04-17 | 2017-06-20 | James B. Mcclain | Stents having controlled elution |
WO2011097103A1 (en) | 2010-02-02 | 2011-08-11 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US9554888B2 (en) | 2010-04-20 | 2017-01-31 | University Of Utah Research Foundation | Phase separation sprayed scaffold |
WO2011133655A1 (en) | 2010-04-22 | 2011-10-27 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US20130172853A1 (en) | 2010-07-16 | 2013-07-04 | Micell Technologies, Inc. | Drug delivery medical device |
WO2012166819A1 (en) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
CA2841360A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US9889235B2 (en) | 2013-02-05 | 2018-02-13 | University Of Utah Research Foundation | Implantable devices for bone or joint defects |
CN110269959A (en) | 2013-03-12 | 2019-09-24 | 脉胜医疗技术公司 | Bioabsorbable biomedical implants |
US10272606B2 (en) | 2013-05-15 | 2019-04-30 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07107055B1 (en) | 1990-04-25 | 1995-11-15 | ||
CA2063055A1 (en) * | 1991-05-22 | 1992-11-23 | Jacob Eyal | Peptides having thrombospondin-like activity and their therapeutic use |
JP3666042B2 (en) * | 1994-01-25 | 2005-06-29 | 日産化学工業株式会社 | Pyridazinone derivatives |
IL112695A (en) * | 1994-02-22 | 1999-04-11 | Green Cross Corp | Pharmaceutical compositions containing pyridazinone derivatives |
-
1998
- 1998-08-26 AT AT98940584T patent/ATE307584T1/en active
- 1998-08-26 ES ES98940584T patent/ES2247716T3/en not_active Expired - Lifetime
- 1998-08-26 WO PCT/JP1998/003820 patent/WO1999011268A1/en active IP Right Grant
- 1998-08-26 JP JP2000508370A patent/JP4352613B2/en not_active Expired - Fee Related
- 1998-08-26 AU AU88862/98A patent/AU8886298A/en not_active Abandoned
- 1998-08-26 US US09/486,327 patent/US6284758B1/en not_active Expired - Lifetime
- 1998-08-26 CA CA002301852A patent/CA2301852C/en not_active Expired - Fee Related
- 1998-08-26 EP EP98940584A patent/EP1025847B1/en not_active Expired - Lifetime
- 1998-08-26 CN CNB988105799A patent/CN1142779C/en not_active Expired - Fee Related
- 1998-08-26 DE DE69832089T patent/DE69832089T2/en not_active Expired - Lifetime
- 1998-08-26 KR KR1020007001968A patent/KR100559192B1/en not_active IP Right Cessation
- 1998-08-26 DK DK98940584T patent/DK1025847T3/en active
- 1998-08-27 TW TW087114142A patent/TW490303B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1025847B1 (en) | 2005-10-26 |
CN1142779C (en) | 2004-03-24 |
US6284758B1 (en) | 2001-09-04 |
TW490303B (en) | 2002-06-11 |
ES2247716T3 (en) | 2006-03-01 |
DK1025847T3 (en) | 2006-02-13 |
CN1277553A (en) | 2000-12-20 |
AU8886298A (en) | 1999-03-22 |
CA2301852A1 (en) | 1999-03-11 |
ATE307584T1 (en) | 2005-11-15 |
WO1999011268A1 (en) | 1999-03-11 |
JP4352613B2 (en) | 2009-10-28 |
KR20010023331A (en) | 2001-03-26 |
DE69832089T2 (en) | 2006-07-20 |
DE69832089D1 (en) | 2005-12-01 |
EP1025847A1 (en) | 2000-08-09 |
KR100559192B1 (en) | 2006-03-13 |
EP1025847A4 (en) | 2003-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2301852C (en) | Angiogenesis promoters and angiogenesis potentiators | |
WO1995014384A1 (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
JP2011256195A (en) | At1-receptor antagonist for preventing and treating postischemic renal failure and for protecting ischemic kidney | |
JPH02121935A (en) | Drug for curing cerebral paralysis | |
KR20010112474A (en) | Use of Dopamine D3 Receptor Ligands for Producing Medicaments for Treating Kidney Disorders | |
EP0771563B1 (en) | Use of 5-HT1A receptor ligands for the treatment of glaucoma | |
US20090253665A1 (en) | Method of treatment of disease using an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
JP2814600B2 (en) | Drugs for dysuria | |
EP0682947A1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
JPWO2006118212A1 (en) | Preventive and therapeutic agent for pancreatitis | |
AU2004216133A1 (en) | Adenosine A1 receptor antagonist for the treatment of cardiac and renal diseases | |
TW200817401A (en) | KW-3902 conjugates that do not cross the blood-brain barrier | |
JP4836388B2 (en) | Preventive or therapeutic agent for diseases caused by eNOS expression | |
CA2120319C (en) | Pharmaceutical for the treatment of skin disorders | |
JP2005516977A (en) | Use of 4- (2-fluorophenyl) -6-methyl-2- (1-piperazinyl) thieno (2,3-D-pyrimidine) in the treatment of urinary incontinence | |
KR20070029133A (en) | Drug for inhibiting vascular intimal hyperplasia | |
JPH0119A (en) | Renal function improving agent | |
JPH0737388B2 (en) | Renal function improving agent | |
AU2006261296B9 (en) | Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder | |
JP2949366B2 (en) | Agent for preventing or treating heart disease | |
KR20110073575A (en) | Agent for treatment of diabetic nephropathy | |
KR20050042803A (en) | Drug for kidney failure containing oxaluric acid derivative | |
JP2004537545A (en) | Pyridin-2-yl-methylamine derivatives for the treatment of opioid dependence | |
WO1997007806A1 (en) | Preventive or remedy for kidney diseases | |
EP0272849A2 (en) | Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160826 |